EORTC Phase II trabectedin study opens for meningioma patients

(European Organisation for Research and Treatment of Cancer) EORTC and PharmaMar announced today the opening of a Phase II trial (EORTC 1320 trial) with YONDELIS® (trabectedin) in patients with recurrent high grade meningioma to assess its efficacy and safety compared to standard of care.